pharma · Diabetes Mellitus · Hemophilia A
Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179
Phase 3 · small molecule · Schizophrenia
SPD489 is a small-molecule investigational antipsychotic developed by Takeda for the treatment of schizophrenia. The program entered Phase 3 clinical development and evaluated low-dose formulations (40 mg, 80 mg, and 100 mg). As of June 2021, the most recent disclosed milestone involved assessment of the low-dose range
Internal code SPD489-335
SPD489 is a small-molecule investigational antipsychotic developed by Takeda for the treatment of schizophrenia. The program entered Phase 3 clinical development and evaluated low-dose formulations (40 mg, 80 mg, and 100 mg). As of June 2021, the most recent disclosed milestone involved assessment of the low-dose range. The program has since been terminated, indicating Takeda discontinued further development. The mechanism of action and specific molecular target remain not yet disclosed in available sources. SPD489 was evaluated in at least one pivotal trial (NCT01760889) in the schizophrenia indication. The termination status suggests the program did not advance to regulatory filing or approval. No peak sales projections or consensus analyst positions have been disclosed for this asset.
Schizophrenia remains a significant unmet medical need affecting millions globally, with persistent challenges in treatment efficacy, tolerability, and patient adherence. Antipsychotic medications represent a cornerstone of schizophrenia management, yet many patients experience inadequate symptom control or dose-limiting adverse effects with existing therapies. The development of low-dose formulations addresses a key clinical objective: maintaining therapeutic efficacy while potentially reducing side-effect burden and improving tolerability profiles. SPD489's low-dose strategy positioned it within a competitive landscape dominated by established agents including aripiprazole, paliperidone ER, and clozapine, as well as emerging therapies. The termination of SPD489 suggests that clinical efficacy, safety, or commercial viability assessments did not support continued investment by Takeda. The schizophrenia market remains substantial, with multiple approved antipsychotics and ongoing development of novel mechanisms. SPD489's discontinuation reflects the high attrition rate in psychiatric drug development and the stringent efficacy and safety thresholds required for competitive positioning in this therapeutic area.
SPD489 is a small-molecule antipsychotic candidate. The specific mechanism of action, molecular target, and route of administration are not yet disclosed. The drug was evaluated in low-dose formulations ranging from 40 mg to 100 mg. Related approved antipsychotics in the competitive set include aripiprazole, paliperidone ER, clozapine, and iloperidone, all of which are small-molecule agents with established efficacy in schizophrenia. Patent status and first approval date are not applicable given the program's terminated status.
Also known as: schizophrenia 12, schizophrenia (disease), SCZD
A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.
ClinicalTrials.gov lists 2,921 registered studies for Schizophrenia (AACT aggregate).
Phase breakdown: NA (1,441), PHASE4 (414), PHASE3 (377), PHASE2 (297), PHASE1 (276), PHASE1/PHASE2 (52), PHASE2/PHASE3 (42), EARLY_PHASE1 (22)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005090), Orphanet — schizophrenia, NCT00000371, NCT00000372, NCT00000374, NCT00000387, NCT00001192, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 3 ongoing
SPD489 Phase 3 trial (NCT01760889) in schizophrenia evaluating low-dose formulations.
Latest disclosed milestone
SPD489 low-dose range (40 mg, 80 mg, 100 mg) under evaluation.
Program terminated
SPD489 development discontinued; no further advancement to regulatory filing.
SPD489 operated within a mature and competitive antipsychotic market dominated by multiple approved small-molecule agents. Key competitors include aripiprazole (Otsuka Beijing Research Institute), paliperidone ER (Hospital Authority, Hong Kong), clozapine (Bright Minds Biosciences), and iloperidone (Vanda Pharmaceuticals). Takeda itself markets vortioxetine and ramelteon in the psychiatric space. Long-acting formulations such as PERSERIS (Indivior) represent an alternative delivery strategy. Adjunctive agents including valbenazine (Neurocrine Biosciences) and minocycline (Bright Minds Biosciences) address specific symptom domains. SPD489's low-dose strategy aimed to differentiate through improved tolerability, yet the program's termination indicates it did not achieve sufficient competitive advantage or clinical validation to justify continued development against this established field of approved alternatives.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Clozapine | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Iloperidone | Vanda Pharmaceuticals Netherlands B.V. | small_molecule | approved |
| Ramelteon | Takeda | small_molecule | approved |
| PERSERIS | Indivior Pty Ltd | small_molecule | approved |
| INTENSIFY SZ | Disc Medicine | small_molecule | approved |
| Varenicline | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Aripiprazole | Otsuka Beijing Research Institute | small_molecule | approved |
| Paliperidone ER | Hospital Authority, Hong Kong | small_molecule | approved |
| Vortioxetine | Takeda | small_molecule | approved |
| Valbenazine | NEUROCRINE BIOSCIENCES INC | small_molecule | approved |
| Minocycline | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Dexmedetomidine | BioXcel Therapeutics | small_molecule | approved |
| ZIPRASIDONE HYDROCHLORIDE | — | Dopamine D2 receptor antagonist | Approved |
| TRIFLUOPERAZINE HYDROCHLORIDE | — | D2-like dopamine receptor antagonist | Approved |
| THIOTHIXENE | — | Dopamine D2 receptor antagonist | Approved |
| SAMIDORPHAN L-MALATE | — | Delta opioid receptor partial agonist | Approved |
| RISPERIDONE | — | Serotonin 2a (5-HT2a) receptor antagonist | Approved |
| QUETIAPINE FUMARATE | — | Serotonin 2c (5-HT2c) receptor antagonist | Approved |
| PROCHLORPERAZINE | — | Dopamine D2 receptor antagonist | Approved |
| PERPHENAZINE | — | Dopamine D2 receptor antagonist | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
SPD489 did not advance to regulatory filing or approval. The program was terminated during Phase 3 development. Regulatory status across major jurisdictions (FDA, EMA, PMDA, NMPA) remains not yet disclosed, as the asset did not progress to submission. A related clinical trial (NCT05478356) is noted as being in clinical trials status in China (NMPA), though the relationship between this trial identifier and SPD489 development is not explicitly clarified in the available facts.
SPD489 is an investigational antipsychotic developed for the treatment of schizophrenia. The program has been terminated and is not approved for clinical use.
No. SPD489 did not advance to regulatory filing or approval. The program was terminated during Phase 3 development.
The specific mechanism of action of SPD489 is not yet disclosed in available sources.
SPD489 is developed by Takeda Pharmaceutical Company. The program has been terminated.
SPD489 was evaluated in Phase 3 trial NCT01760889 in schizophrenia patients. Results have not yet been reported, and the program has been terminated.
SPD489 was evaluated in low-dose formulations of 40 mg, 80 mg, and 100 mg as of the most recent disclosed milestone in June 2021.
The specific reasons for termination are not yet disclosed. Termination during Phase 3 typically reflects insufficient efficacy, safety concerns, or lack of competitive differentiation.
The specific molecular target of SPD489 is not yet disclosed.
The route of administration for SPD489 is not yet disclosed.
SPD489 competes with approved antipsychotics including aripiprazole, paliperidone ER, clozapine, iloperidone, and other established agents in the schizophrenia market.
The first disclosure date for SPD489 is not yet disclosed. The most recent milestone was disclosed on June 22, 2021.
SPD489 is a small-molecule antipsychotic candidate.
SPD489 is terminated. No further development is anticipated.
No partner is disclosed for SPD489. Takeda is the sole sponsor of the program.
Projected peak sales for SPD489 are not yet disclosed.
Consensus analyst position on SPD489 is not yet disclosed.
SPD489-335 → Drug → Target → Indication → Company → Trials → Competitors
SPD489's termination reflects the high attrition rate in antipsychotic development and the substantial clinical and commercial hurdles required for competitive entry. The program's discontinuation during Phase 3 suggests that interim efficacy, safety, or pharmacokinetic data did not support advancement to regulatory submission. Takeda's decision to terminate indicates either insufficient differentiation from established agents or tolerability/efficacy concerns that precluded competitive positioning.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.